John Mantsch

Corporate Officer/Principal presso Marquette University

Consumer Services

Health Technology

Profilo

John Mantsch is the founder of Promentis Pharmaceuticals, Inc. which was founded in 2007.
Currently, he is the Chairman of the Biomedical Sciences Department at Marquette University.
Dr. Mantsch completed his undergraduate degree at Allegheny College and his doctorate at Louisiana State University Shreveport.

Posizioni attive di John Mantsch

Società	Posizione	Inizio
Marquette University	Corporate Officer/Principal	-

Tutte le posizioni attive di John Mantsch

Precedenti posizioni note di John Mantsch

Società	Posizione	Fine
Promentis Pharmaceuticals, Inc. Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI.	Founder	-

Vedi nel dettaglio l'esperienza di John Mantsch

Formazione di John Mantsch

Allegheny College	Undergraduate Degree
Louisiana State University Shreveport	Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di John Mantsch

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	1
Promentis Pharmaceuticals, Inc. Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI.	Health Technology